324 related articles for article (PubMed ID: 27035987)
1. Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model.
Silva A; Lee BY; Clemens DL; Kee T; Ding X; Ho CM; Horwitz MA
Proc Natl Acad Sci U S A; 2016 Apr; 113(15):E2172-9. PubMed ID: 27035987
[TBL] [Abstract][Full Text] [Related]
2. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomic Signatures Predict Regulators of Drug Synergy and Clinical Regimen Efficacy against Tuberculosis.
Ma S; Jaipalli S; Larkins-Ford J; Lohmiller J; Aldridge BB; Sherman DR; Chandrasekaran S
mBio; 2019 Nov; 10(6):. PubMed ID: 31719182
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
7. New treatment options for multidrug-resistant tuberculosis.
Field SK; Fisher D; Jarand JM; Cowie RL
Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
[TBL] [Abstract][Full Text] [Related]
8. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
9. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis.
Ahmad S; Mokaddas E
J Infect Public Health; 2014; 7(2):75-91. PubMed ID: 24216518
[TBL] [Abstract][Full Text] [Related]
10. Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time.
Lee BY; Clemens DL; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
Nat Commun; 2017 Jan; 8():14183. PubMed ID: 28117835
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
12. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis.
Tyagi S; Ammerman NC; Li SY; Adamson J; Converse PJ; Swanson RV; Almeida DV; Grosset JH
Proc Natl Acad Sci U S A; 2015 Jan; 112(3):869-74. PubMed ID: 25561537
[TBL] [Abstract][Full Text] [Related]
13. Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes.
Xu Y; Wu J; Liao S; Sun Z
Ann Clin Microbiol Antimicrob; 2017 Oct; 16(1):67. PubMed ID: 28974222
[TBL] [Abstract][Full Text] [Related]
14. Intracellular Accumulation of Novel and Clinically Used TB Drugs Potentiates Intracellular Synergy.
Tanner L; Mashabela GT; Omollo CC; de Wet TJ; Parkinson CJ; Warner DF; Haynes RK; Wiesner L
Microbiol Spectr; 2021 Oct; 9(2):e0043421. PubMed ID: 34585951
[TBL] [Abstract][Full Text] [Related]
15. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
Centers for Disease Control and Prevention (CDC)
MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
[TBL] [Abstract][Full Text] [Related]
17. In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates.
Zhang Z; Li T; Qu G; Pang Y; Zhao Y
Int J Antimicrob Agents; 2015 Jan; 45(1):71-5. PubMed ID: 25459737
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance in Mycobacterium tuberculosis strains isolated from re-treatment cases of pulmonary tuberculosis in Ethiopia: susceptibility to first-line and alternative drugs.
Abate G; Miörner H; Ahmed O; Hoffner SE
Int J Tuberc Lung Dis; 1998 Jul; 2(7):580-4. PubMed ID: 9661826
[TBL] [Abstract][Full Text] [Related]
19. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
20. Managing TB in the 21st century: existing and novel drug therapies.
Guy ES; Mallampalli A
Ther Adv Respir Dis; 2008 Dec; 2(6):401-8. PubMed ID: 19124385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
